Latest Development Program News

Telix Pharmaceuticals has lodged a European marketing authorization application for TLX101-Px, a novel PET imaging agent targeting glioma brain cancer, aiming to enhance diagnostic precision and patient access across major European markets.

Nexalis Therapeutics has completed a key capital raising milestone, issuing new shares, options, and performance rights following shareholder approval. This move supports the company’s clinical-stage drug development programs targeting pain and mental health.

Matsa Resources launches a major drilling campaign at Fortitude North targeting up to 1.85 million ounces of gold, supported by a $17.5 million loan facility from major shareholder Deutsche Balaton.

Neuren Pharmaceuticals has initiated a discretionary on-market share buy-back program of up to 5%, citing a strong cash position and undervaluation relative to internal and analyst assessments.

Paradigm Biopharmaceuticals has published a pivotal study in PLOS ONE showing sustained pain relief and joint repair in dogs treated with pentosan polysulfate sodium, reinforcing its potential for human osteoarthritis therapy.

Racura Oncology has developed a pioneering blood test that promises to fast-track key data on its cardioprotective drug RC220, potentially shaving two years off the clinical trial timeline. This innovation also enhances patient safety and recruitment prospects in the ongoing RAC-010 CPACS trial.

Brightstar Resources has reported impressive high-grade gold assay results from its 2025 drilling campaign at the Sandstone Hub, setting the stage for a significant Mineral Resource upgrade and Pre-Feasibility Study later this year.

PYC Therapeutics has successfully closed a $537 million institutional placement and entitlement offer, positioning the company to raise at least $600 million to advance its RNA-based therapies targeting genetic diseases.

Strickland Metals has successfully raised A$55 million through an institutional placement to accelerate exploration and advance a Pre-Feasibility Study at its Rogozna Project in Serbia.

OncoSil Medical Limited has announced a fully underwritten $2 million entitlement offer alongside a $6 million placement to fund its clinical and commercial growth initiatives. The capital raising includes new shares and options, with shareholder approvals pending for certain components.

BMG Resources has raised $2.5 million in a placement led by Tribeca Investment Partners to fund an expanded drilling program at its Abercromby Gold Project and advance exploration at Bullabulling. The company also welcomes Ben Pollard as its new CEO to spearhead growth.

Argenica Therapeutics has won a crucial regulatory waiver from the European Medicines Agency, removing the need for paediatric trials for its stroke drug ARG-007 and clearing the way for faster adult market approval in Europe.